



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 Of 4

Complete if Known

Application Number	10/621,435
Filing Date	July 17, 2003
First Named Inventor	Codd, et al.
Art Unit	1724
Examiner Name	N/A
Attorney Docket Number	DOVP-1-0901

U.S. PATENT DOCUMENTS

Exam. Initials	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
9/1	AA	US- 4,022,652	05/10/77	Hirano, et al	
	AB	US- 4,088,652	05/09/78	Fanshawe, et al	
	AC	US- 4,118,393	10/03/78	Fanshawe, et al	
	AD	US- 4,118,417	10/03/78	Epstein	
	AE	US- 4,131,611	12/26/78	Fanshawe, et al	
	AF	US- 4,338,268	08/22/82	Bruderer, et al	
	AG	US- 4,435,419	05/06/84	Epstein, et al	
	AH	US- 4,504,657	03/12/85	Bouzard, et al	
	AI	US- 4,521,431	08/04/85	Crookes	
	AJ	US- 4,591,598	05/27/86	Urbach, et al	
	AK	US- 5,039,680	08/13/91	Imperato, et al	
	AL	US- 5,075,341	12/24/91	Mendelson, et al	
	AM	US- 5,130,430	07/14/92	Shaw	
	AN	US- 5,198,459	03/30/93	Imperato, et al	
	AO	US- 5,232,934	08/03/93	Downs	
	AP	US- 5,488,056	01/30/96	Bodick, et al	
	AQ	US- 5,556,837	09/17/96	Nestler, et al	
	AR	US- 5,556,838	09/17/96	Mayer, et al	
	AS	US- 5,574,052	11/12/96	Rose, et al	
	AT	US- 5,969,156	10/19/99	Briggs, et al	
	AU	US- 5,985,864	11/16/99	Imai, et al	
	AV	US- 6,245,911	06/12/01	Imai, et al	
	AW	US-3,892,722	07/01/75	Hoffman, et al	
	AX	US-5,762,925	06/09/98	Sagen	
	AY	US-5,911,992	06/15/99	Braswell, et al.	
	AZ	US-6,109,269	08/29/00	Rise, et al	
	BA	US-6,121,261	09/19/00	Glatt, et al	
	BB	US-6,194,000	02/27/01	Smith, et al	
	BC	US-6,204,284	03/20/01	Beer, et al	
	BD	US-6,372,919	04/18/02	Lippa, et al	
	BE	US-6,569,887	05/27/03	Lippa, et al	
	BF	US-6,716,868	04/06/04	Lippa, et al	
	BG	USSN 10/764,371 2004-0157869	08/12/04	Lippa, et al	
	BH	USSN 10/764,373 2004-0157870	08/12/04	Lippa, et al	
	BI	USSN 10/764,375 2004-0157908	08/12/04	Lippa, et al	
	BJ	USSN 10/702,397 2004-01002638	05/27/04	Russell, et al	
9/1	BK	USSN 10/466,457 2004-0127541	07/08/04	Lippa, et al.	

FOREIGN PATENT DOCUMENTS							
Exam. Initials	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear.	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)					
9/1	BL	BE 858,683		12/30/82	BE (In French w/English Abstract)		
9/1	BM	BE 893,707		12/30/82	BE (In French w/English Abstract)		
Examiner Signature		Q. [Signature]			Date Considered	1/26/2006	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

Of

4

Complete if Known

Application Number	10/621,435
Filing Date	July 17, 2003
First Named Inventor	Codd, et al.
Art Unit	1724
Examiner Name	N/A
Attorney Docket Number	DOVP-1-0901

NON PATENT LITERATURE DOCUMENTS

Exam. Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
9A	BN	BALDESSARINI, R. <u>Drugs and The Treatment of Psychiatric Disorders</u> . Goodman & Gilman's The Pharmacological Basis of Therapeutics 9 th Edition. Hardman et al. eds. 1996. p. 399 and Ch 18:431-459, McGraw-Hill, New York	
	BO	BAYES, et al., Gateways to clinical trials - Allosteric Interaction Between The Site Labeled By [3H]mipramine And The Serotonin Transporter In Human Platelets. The oral analgesic activity of 1-aryl-3-azabicyclo[3.1.0]hexanes 1-aryl-3-azabicyclo[3.1.0]hexanes, a new series of non-narcotic analgesic agents. Methods Find Exp. Clin. Pharmacol. Apr Feb May 2003; 25(3):225-248.	
	BP	BLUM, et al., <u>Dopamine D2 Receptor Gene Variants; Association and Linkage Studies In Impulsive-Addictive-Compulsive Behavior</u> . Pharmacogenetics 5:121-141, 1996.	
	BQ	BRAY, G. <u>A Concise Review On The Therapeutics of Obesity</u> . Nutrition 16:953-960, 2000.	
	BR	CROWN, W. <u>Economic Outcomes Associated With Tricyclic Antidepressant And Selective Serotonin Reuptake Inhibitor Treatments For Depression</u> . Acta Psychiatr. Supp. 2000; 403:62-6.	
	BS	CZOBOR, P. <u>A Double-Blind, Placebo Controlled Randomized Study of DOV 220,075 (Bicifadine) SR and Codeine 60 mg in The Treatment of Post-Operative Dental Pain</u> . Abstract (915). American Pain Society (2003).	
	BT	D'AQUILA, et al, <u>The Role Of Dopamine In The Mechanism of Action of Antidepressant Drugs</u> . Eur. J. Pharmacol. 405:365-373, 2000.	
	BU	EPSTEIN, et al., <u>1-ARYL-3-AZABICYCLO[3.1.0]HEXANES, A New Series of Non-Narcotic Analgesic Agents</u> . J. Med. Chem. 24(5):481-90, 1981.	
	BV	FRAZER, A. <u>Norepinephrine Involvement In Antidepressant Action</u> . J. Clin. Psychiatry. 61(10):25-30, 2000.	
	BW	FREDMAN, et al., <u>Partial Response, Nonresponse, and Relapse With Selective Serotonin Reuptake Inhibitors In Major Depression: A Survey of Current "Next-Step" Practices</u> . J. Clin. Psychiatry 61(6):403-8, 2000.	
	BX	HACKH's Chemical Dictionary, 4 th Edition, 1969, Julius Grant, ed., McGraw-Hill Book Company, New York, pp. 474-75	
	BY	HARRISON's Principles of Internal Medicine 2485-2503 (Fauci, et al., eds., 14 th ed. 1998)	
9A	BZ	HITRI, et al., <u>Molecular, Functional and Biochemical Characteristics of The Dopamine Transporter: Regional Differences and Clinical Relevance</u> . J. Clin. Pharmacol. 17:1-22, 1994.	

91	CA	HOFFMAN, et al., <u>Localization and Dynamic Regulation of Biogenic Amine Transporters In The Mammalian Central Nervous System</u> . Front. In Neuroendocrinol. 19(3): 187-213, 1998.	
	CB	KIYATKIN, E. <u>Dopamine Mechanisms of Cocaine Addition</u> . Int. J. Neurosci. 78:75-101, 1994.	
	CC	KREEK, M. <u>Cocaine, Dopamine and The Endogenous Opioid System</u> . J. Addict. Dis. 15:73-96, 1996.	
	CD	LEONHARDT, et al., <u>New Approaches In The Pharmacological Treatment of Obesity</u> . Eur. J. Nutr. 38:1-13, 1999.	
	CE	MEYERSON, et al., <u>Allosteric Interaction Between The Site Labeled by [3H]imipramine and The Serotonin Transporter In Human Platelets</u> . J. Neurochem. 48(2):560-65, 1987.	
	CF	NAGATSU, et al., <u>Changes In Cytokines And Neotrophins In Parkinson's Disease</u> . J. Neural. Transm. Suppl. 60:277-290, 2000.	
	CG	NOBLE, E. <u>Polymorphisms of The D2 Dopamine Receptor Gene and Alcoholism and Other Substance Use Disorders</u> . Alcohol. Supp. 2:35-43, 1994.	
	CH	PORTER, et al., <u>Single Dose Comparison of Bicyclanil, Codeine, and Placebo in Postoperative Pain</u> . Current Therapeutic Research. 30(3):156-160, August 1981.	
	CI	SCATES, et al., <u>Reboxetine: A Selective Norepinephrine Reuptake Inhibitor For The Treatment Of Depression</u> . Ann. Pharmacother. 34(11):1302-12, 2000.	
	CJ	SIMON, et al., <u>TCA's or SSRIs As Initial Therapy For Depression?</u> J. of Family Practice. 48:845-46, 1999.	
	CK	SKOLNICK, et al., <u>"Broad Spectrum" Antidepressants: Is More Better For The Treatment of Depression?</u> Life Sciences 73 (2003) 3175-3179	
	CL	SKOLNICK, et al., <u>Antidepressant-like Actions of DOV 21.947: A "Triple" Reuptake Inhibitor</u> . Eur. J. Pharm. 461 (2003) 99-104	
	CM	STACY, et al., <u>Treatment Options for Early Parkinson's Disease</u> . Am. Fam. Phys. 53:1281-87, 1996.	
	CN	SULLIVAN, et al., <u>Mechanisms of Appetite Modulation By Drugs</u> , Federation Proceedings, Vol. 44, No. 1, Part 1, pp. 139-144, 1985.	
	CO	WONG, et al., <u>Reboxetine: A Pharmacologically Potent, Selective, and Specific Norepinephrine Reuptake Inhibitor</u> . Biol. Psychiatry. 47(9):818-29, 2000.	
	CP	SKOLNICK, P., <u>Beyond Monoamine-Based Therapies: Clues To New Approaches</u> . J. Clin Psychiatry 63:19-23, 2002.	
	CQ	EPSTEIN, et al., <u>Bicyclanil: Non-Narcotic Analgesic Activity of 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES</u> . NIDA Res. Monogr. 41:93-98, 1982.	
91	CR	WANG, et al., <u>The Oral Analgesic Efficacy of Bicyclanil Hydrochloride In Postoperative Pain</u> . J. Clin. Pharmacol. 22(4):160-164, April 1982.	

Examiner Signature	<i>J. Rugg</i>	Date Considered	1/26/2006
-----------------------	----------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/621,435
Filing Date	July 17, 2003
First Named Inventor	Codd, et al.
Art Unit	1724
Examiner Name	N/A
Attorney Docket Number	DOVP-1-0901

Sheet 1 Of 4

U.S. PATENT DOCUMENTS

Exam. Initials	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
9/1	AA	US- 4,022,652	05/10/77	Hirano, et al	
	AB	US- 4,088,652	05/09/78	Fanshawe, et al	
	AC	US- 4,118,393	10/03/78	Fanshawe, et al	
	AD	US- 4,118,417	10/03/78	Epstein	
	AE	US- 4,131,611	12/26/78	Fanshawe, et al	
	AF	US- 4,338,268	06/22/82	Bruderer, et al	
	AG	US- 4,435,419	05/06/84	Epstein, et al	
	AH	US- 4,504,657	03/12/85	Bouzard, et al	
	AI	US- 4,521,431	06/04/85	Crookes	
	AJ	US- 4,591,598	05/27/86	Urbach, et al	
	AK	US- 5,039,680	08/13/91	Imperato, et al	
	AL	US- 5,075,341	12/24/91	Mendelson, et al	
	AM	US- 5,130,430	07/14/92	Shaw	
	AN	US- 5,198,459	03/30/93	Imperato, et al	
	AO	US- 5,232,934	08/03/93	Downs	
	AP	US- 5,488,056	01/30/96	Bodick, et al	
	AQ	US- 5,556,837	09/17/96	Nestler, et al	
	AR	US- 5,556,838	09/17/96	Mayer, et al	
	AS	US- 5,574,052	11/12/96	Rose, et al	
	AT	US- 5,969,156	10/19/99	Briggs, et al	
	AU	US- 5,985,864	11/16/99	Imai, et al	
	AV	US- 6,245,911	08/12/01	Imai, et al	
	AW	US-3,892,722	07/01/75	Hoffman, et al	
	AX	US-5,782,925	06/09/98	Sagen	
	AY	US-5,911,992	06/15/99	Braswell, et al.	
	AZ	US-6,109,269	08/29/00	Rise, et al	
	BA	US-6,121,261	09/19/00	Glat, et al	
	BB	US-6,194,000	02/27/01	Smith, et al	
	BC	US-6,204,284	03/20/01	Beer, et al	
	BD	US-6,372,919	04/16/02	Lippa, et al	
	BE	US-6,569,887	05/27/03	Lippa, et al	
	BF	US-6,716,868	04/06/04	Lippa, et al	
	BG	US 10/764,371 2004-0157869	08/12/04	Lippa, et al	
	BH	US 10/764,373 2004-0157870	08/12/04	Lippa, et al	
	BI	US 10/764,375 2004-0157908	08/12/04	Lippa, et al	
	BJ	US 10/702,397 2004-01002638	05/27/04	Russell, et al	
OK	BK	US 10/486,457 2004-0127541	07/08/04	Lippa, et al.	

FOREIGN PATENT DOCUMENTS						
Exam. Initials	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
QA	BL	BE 858,683		12/30/82	BE (In French w/English Abstract)	
QA	BM	BE 893,707		12/30/82	BE (In French w/English Abstract)	
Examiner Signature		Q. Kopp		Date Considered	1/21/2006	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

Of

4

Complete if Known

Application Number	10/621,435
Filing Date	July 17, 2003
First Named Inventor	Codd, et al.
Art Unit	1724
Examiner Name	N/A
Attorney Docket Number	DOVP-1-0901


NON PATENT LITERATURE DOCUMENTS

Exam. Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
911	BN	BALDESSARINI, R. <u>Drugs and The Treatment of Psychiatric Disorders</u> . Goodman & Gilman's The Pharmacological Basis of Therapeutics 9 th Edition. Hardman et al. eds. 1996. p. 399 and Ch 18:431-459, McGraw-Hill, New York	
	BO	BAYES, et al., Gateways to clinical trials - Allosteric Interaction Between The Site Labeled By [3H]imipramine And The Serotonin Transporter In Human Platelets. The oral analgesic activity of 1-aryl-3-azabicyclo[3.1.0]hexanes 1-aryl-3-azabicyclo[3.1.0]hexanes, a new series of non-narcotic analgesic agents. Methods Find Exp. Clin. Pharmacol. Apr Feb May 2003; 25(3):225-248.	
	BP	BLUM, et al., <u>Dopamine D2 Receptor Gene Variants: Association and Linkage Studies In Impulsive-Addictive-Compulsive Behavior</u> . Pharmacogenetics 5:121-141, 1996.	
	BQ	BRAY, G. <u>A Concise Review On The Therapeutics of Obesity</u> . Nutrition 16:953-960, 2000.	
	BR	CROWN, W. <u>Economic Outcomes Associated With Tricyclic Antidepressant And Selective Serotonin Reuptake Inhibitor Treatments For Depression</u> . Acta Psychiatr. Supp. 2000; 403:62-6.	
	BS	CZOBOR, P. <u>A Two Center Double-Blind, Placebo-Controlled Randomized Study of DOV 220,075 (Bicifadine) SR and Tramadol 100 mg in The Treatment of Post-Operative Dental Pain</u> . Abstract (801). American Pain Society (2004).	
	BT	CZOBOR, P. <u>A Double-Blind, Placebo Controlled Randomized Study of DOV 220,075 (Bicifadine) SR and Codeine 60 mg in The Treatment of Post-Operative Dental Pain</u> . Abstract (915). American Pain Society (2003).	
	BU	D'AQUILA, et al, <u>The Role Of Dopamine In The Mechanism of Action of Antidepressant Drugs</u> . Eur. J. Pharmacol. 405:365-373, 2000.	
	BV	EPSTEIN, et al., <u>1-ARYL-3-AZABICYCLO[3.1.0]HEXANES, A New Series of Non-Narcotic Analgesic Agents</u> . J. Med. Chem. 24(5):481-90, 1981.	
	BW	FRAZER, A. <u>Norepinephrine Involvement In Antidepressant Action</u> . J. Clin. Psychiatry. 61(10):25-30, 2000.	
	BX	FREDMAN, et al, <u>Partial Response, Nonresponse, and Relapse With Selective Serotonin Reuptake Inhibitors In Major Depression: A Survey of Current "Next-Step" Practices</u> . J. Clin. Psychiatry 61(6):403-8, 2000.	
	BY	HACKH's Chemical Dictionary, 4 th Edition, 1969, Julius Grant, ed., McGraw-Hill Book Company, New York, pp. 474-75	
911	BZ	HARRISON's Principles of Internal Medicine 2485-2503 (Fauci, et al., eds., 14 th ed. 1998)	

9H	CA	HITRI, et al., <u>Molecular, Functional and Biochemical Characteristics of The Dopamine Transporter: Regional Differences and Clinical Relevance</u> . J. Clin. Pharmacol. 17:1-22, 1994.	
	CB	HOFFMAN, et al., <u>Localization and Dynamic Regulation of Biogenic Amine Transporters In The Mammalian Central Nervous System</u> . Front. In Neuroendocrinol. 19(3): 187-213, 1998.	
	CC	KIYATKIN, E. <u>Dopamine Mechanisms of Cocaine Addiction</u> . Int. J. Neurosci. 78:75-101, 1994.	
	CD	KREEK, M. <u>Cocaine, Dopamine and The Endogenous Opioid System</u> . J. Addict. Dis. 15:73-96, 1996.	
	CE	LEONHARDT, et al., <u>New Approaches In The Pharmacological Treatment of Obesity</u> . Eur. J. Nutr. 38:1-13, 1999.	
	CF	McCARDLE, et al., <u>"A Method For The Prediction of The Crystal Structure of Ionic Compounds - The Crystal Structures of O-Toluidinium Chloride And Bromide And Polymorphism of Bicifadine Hydrochloride."</u> Cryst. Enc. Comm. 2004; 6(53):303-309.	
	CG	MEYERSON, et al., <u>Allosteric Interaction Between The Site Labeled by [3H]Imipramine and The Serotonin Transporter In Human Platelets</u> . J. Neurochem. 48(2):560-65, 1987.	
	CH	NAGATSU, et al., <u>Changes In Cytokines And Neotrophins In Parkinson's Disease</u> . J. Neural. Transm. Suppl. 60:277-290, 2000.	
	CI	NOBLE, E. <u>Polymorphisms of The D2 Dopamine Receptor Gene and Alcoholism and Other Substance Use Disorders</u> . Alcohol. Supp. 2:35-43, 1994.	
	CJ	PORTER, et al., <u>Single Dose Comparison of Bicifadine, Codeine, and Placebo In Postoperative Pain</u> . Current Therapeutic Research. 30(3):156-160, August 1981.	
	CK	SCATES, et al., <u>Reboxetine: A Selective Norepinephrine Reuptake Inhibitor For The Treatment Of Depression</u> . Ann. Pharmacother. 34(11):1302-12, 2000.	
	CL	SIMON, et al., <u>TCA's or SSRIs As Initial Therapy For Depression?</u> J. of Family Practice. 48:845-46, 1999.	
	CM	SKOLNICK, et al., <u>"Broad Spectrum" Antidepressants: Is More Better For The Treatment of Depression?"</u> Life Sciences 73 (2003) 3175-3179	
	CN	SKOLNICK, et al., <u>Antidepressant-like Actions of DOV 21,947: A "Triple" Reuptake Inhibitor</u> . Eur. J. Pharm. 461 (2003) 99-104	
	CO	STACY, et al., <u>Treatment Options for Early Parkinson's Disease</u> . Am. Fam. Phys. 53:1281-87, 1996.	
	CP	SULLIVAN, et al., <u>Mechanisms of Appetite Modulation By Drugs</u> . Federation Proceedings, Vol. 44, No. 1, Part 1, pp. 139-144, 1985.	
	CQ	WONG, et al., <u>Reboxetine: A Pharmacologically Potent, Selective, and Specific Norepinephrine Reuptake Inhibitor</u> . Biol. Psychiatry. 47(9):818-29, 2000.	
	CR	BEER, et al <u>DOV 216,303, a "Triple" Reuptake Inhibitor. Safety, Tolerability, and Pharmacokinetic Profile</u> , J. Clin. Pharmacol. 44:1360-1367, 2004.	
	CS	SKOLNICK, P., <u>Beyond Monoamine-Based Therapies: Clues To New Approaches</u> . J. Clin Psychiatry 63:19-23, 2002.	
	CT	EPSTEIN, et al., <u>Bicifadine: Non-Narcotic Analgesic Activity of 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES</u> . NIDA Res. Monogr. 41:93-98, 1982.	
9H	CU	WANG, et al., <u>The Oral Analgesic Efficacy of Bicifadine Hydrochloride In Postoperative Pain</u> . J. Clin. Pharmacol. 22(4):160-164, April 1982.	

Examiner Signature	<i>J. Nuy</i>	Date Considered	1/26/2006
-----------------------	---------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Form PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

INFORMATIONAL PURPOSE CITATION

(Use several sheets if necessary)

Atty. Docket No.

102458-40932

Serial No.

10/621,435

Applicant:

Codd et al.

Filing Date: July 17, 2003

Art Unit: 1724

U. S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-class	Filing Date If Appropriate
9h	4 1 9 6 1 2 0	4-1-1980	Fanshawe et al.			
9h	4 2 3 1 9 3 5	11-4-1980	Fanshawe et al.			

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Office	Foreign Patent Document Document Number	Date of Publication of Cited Document	Name of Patentee or Applicant of Cited Document.	Class	Sub-class	Translation
							Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Page, Etc.)

Examiner	Date Considered
9h	1/26/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.